<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=545163149217500&amp;ev=PageView&amp;noscript=1">

TherOx® SuperSaturated Oxygen (SSO2) Therapy

TherOx® SuperSaturated Oxygen (SSO2) Therapy

1 in 5 Patients Develop Heart Failure Following an AMI

1 in 5 Patients Develop Heart Failure Following an AMI1

Introducing the Next Frontier in STEMI Care

Introducing the Next Frontier in STEMI Care

Increased Risk of HF with Larger Infarcts
left_arrow Increased Risk of HF with Larger Infarcts1 26% Infarct Size Reduction2left_arrow
DS2-full-new-screen-clipped-1

What you do now, matters for a lifetime

Harness the healing power of SuperSaturated Oxygen (SSO2) Therapy to reduce the risk of heart failure

Vizient LockUp_Hi_ContractedSupplier_black

TherOx® SuperSaturated Oxygen (SSO2) Therapy

The first FDA-approved, catheter-based therapy to safely and effectively reduce infarct size in randomized control trials.2,3

The Next Frontier in STEMI

Delivers localized hyperoxemic levels of oxygen to treat ischemic myocardium, without impacting door-to-balloon time.

Brochure
2 6%

Infarct Size Reduction

Studies show 26% relative infarct size reduction and improvement of left ventricular function in LAD STEMI.2,3,4,5

Publication

Low Rate of Death and Heart Failure at 1 Year

Treatment with SSO2 was associated with a lower 1-year rate of all-cause death or new-onset heart failure (HF) of hospitalization for HF (0.0% vs. 12.3%, p = .001).6

Publication
Reduce endothelial edema and restore microvascular flow to reduce infarct size.

SuperSaturated Oxygen (SSO2) Therapy has been shown to reduce endothelial swelling and restore microvascular flow, leading to reductions in infarct size.7*

90% of myocardial blood flow is supplied by the microvasculature.8

Microvascular obstruction is strongly associated with mortality and heart failure hospitalization within 1 year.9

Significant Clinical Benefit

A 26% relative reduction in infarct size has been correlated with relative reductions in both death and heart failure hospitalization of ~25% at 1 year.4

Infarct Size Reduction with SSO2 vs. Standard of Care2

Infarct Size Reduction with SSO2 vs Standard of Care

A 41% relative reduction in infarct size observed for patients receiving PCI ≤ 3 hours of symptom onset10

Left Ventricular Recovery Demonstrated at 30 Days4,5

Left Ventricular Recovery Demonstrated at 30 Days

SSO2 Therapy demonstrates reduced LV remodeling at 30 days4,5

SSO2 relieves microvascular obstruction to reperfuse ischemic myocardium.

How TherOx SSO2 Therapy Works

Capillary constriction continues post-PCI

Capillary constriction continues post-PCI

Despite successful PCI, endothelial edema occurs and restricts microvascular flow.

Despite successful PCI, endothelial edema occurs and restricts microvascular flow.

Highly concentrated O2 diffuses into endothelial and myocardial tissue

Highly concentrated O2 diffuses into endothelial and myocardial tissue

SSO2 Therapy delivers high levels of dissolved O2 (pO2 = 760-1000mmHg), via the plasma, even before flow is restored downstream.

SSO2 Therapy delivers high levels of dissolved O2 (pO2 = 760-1000mmHg), via the plasma, even before flow is restored downstream.

Microvascular flow is restored and ischemic myocardium reperfused

Microvascular flow is restored and ischemic myocardium reperfused

Endothelial edema is resolved, restoring capillary flow and reperfusing ischemic myocardium.

Endothelial edema is resolved, restoring capillary flow and reperfusing ischemic myocardium.

Publications, News & Updates

Patient treated with SSO2 survives his "widow maker" heart attack.

Watch Video Now
Watch Video Now

Read the winning cases from our TCT Cases & Cocktails Fellows Competition, published in Cardiac Interventions Today.

Read the article

Daytime Chicago segment featuring Sandeep Nathan, MD on SSO2 Therapy

Watch Video Now
Watch Video Now

Novel Therapeutic Strategies to Reduce Reperfusion Injury After AMI

Read the article

ZOLL Awarded Diagnostic and Interventional Cardiology Catheter Agreement with Premier, Inc. for
TherOx SuperSaturated Oxygen Therapy

Read the article

Please refer to IFU for full cautions, warnings and Indications for Use.

Caution: Federal law restricts this device to sale by or on the order of a physician.

Indications For Use: The TherOx DownStream System is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.

© 2024 ZOLL Medical Corporation, Chelmsford, MA, USA. TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

DS2-full-new-screen-clipped-1
ZOLL